Kirill Pavlov1, Joost Kluiver2, Coby Meijer3, Wytske Boersma-van Ek1, Frank A E Kruyt3, Arend Karrenbeld2, Jan H Kleibeuker1, Frans T M Peters1, Anke van den Berg2. 1. Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Diagnostic screening of premalignant esophageal lesions is hampered by the absence of biomarkers indicative of metaplastic and/or malignant transformation. The aim of this exploratory study was to investigate the potential use of miRNAs as biomarkers capable of identifying patients with (pre)malignant lesions: Barrett's esophagus (BE) metaplasia, high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). METHODS: A total of 69 patients were included in the study. Six serum samples from each of four study groups, i.e., patients with normal squamous epithelium (SE), BE, HGD and EAC, were profiled using the Nanostring miRNA analysis platform. Differential miRNA expression patterns then were validated in 69 patient samples using qRT-PCR. RESULTS: miRNA expression profiling revealed seven miRNAs with a 2-fold change in expression level. Validation by qRT-PCR confirmed that serum miR-320e levels were significantly decreased in the BE group compared to the SE (P≤0.001, AUC 0.790) and HGD groups (P≤0.005, AUC 0.786). Serum miR-199a-3p levels were significantly decreased in the BE group compared to the SE group (P≤0.001), area under the curve (AUC) of 0.813. CONCLUSIONS: The results of this study suggest that decreased serum miRNA levels of miR-199a-3p and miR-320e could help to identify patients with BE and HGD.
BACKGROUND: Diagnostic screening of premalignant esophageal lesions is hampered by the absence of biomarkers indicative of metaplastic and/or malignant transformation. The aim of this exploratory study was to investigate the potential use of miRNAs as biomarkers capable of identifying patients with (pre)malignant lesions: Barrett's esophagus (BE) metaplasia, high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). METHODS: A total of 69 patients were included in the study. Six serum samples from each of four study groups, i.e., patients with normal squamous epithelium (SE), BE, HGD and EAC, were profiled using the Nanostring miRNA analysis platform. Differential miRNA expression patterns then were validated in 69 patient samples using qRT-PCR. RESULTS: miRNA expression profiling revealed seven miRNAs with a 2-fold change in expression level. Validation by qRT-PCR confirmed that serum miR-320e levels were significantly decreased in the BE group compared to the SE (P≤0.001, AUC 0.790) and HGD groups (P≤0.005, AUC 0.786). Serum miR-199a-3p levels were significantly decreased in the BE group compared to the SE group (P≤0.001), area under the curve (AUC) of 0.813. CONCLUSIONS: The results of this study suggest that decreased serum miRNA levels of miR-199a-3p and miR-320e could help to identify patients with BE and HGD.
Authors: Francesca Fornari; Maddalena Milazzo; Pasquale Chieco; Massimo Negrini; George Adrian Calin; Gian Luca Grazi; Daniela Pollutri; Carlo Maria Croce; Luigi Bolondi; Laura Gramantieri Journal: Cancer Res Date: 2010-05-25 Impact factor: 12.701
Authors: Colin C Pritchard; Evan Kroh; Brent Wood; Jason D Arroyo; Katy J Dougherty; Melanie M Miyaji; Jonathan F Tait; Muneesh Tewari Journal: Cancer Prev Res (Phila) Date: 2011-12-12
Authors: Douglas A Corley; Theodore R Levin; Laurel A Habel; Noel S Weiss; Patricia A Buffler Journal: Gastroenterology Date: 2002-03 Impact factor: 22.682
Authors: Andrew Feber; Liqiang Xi; James D Luketich; Arjun Pennathur; Rodney J Landreneau; Maoxin Wu; Scott J Swanson; Tony E Godfrey; Virginia R Litle Journal: J Thorac Cardiovasc Surg Date: 2007-12-26 Impact factor: 5.209
Authors: Jessica L Petrick; Ruth M Pfeiffer; Linda M Liao; Christian C Abnet; Xiaolin Wu; Marilie D Gammon; Thomas L Vaughan; Michael B Cook Journal: Dig Dis Sci Date: 2021-01-06 Impact factor: 3.199
Authors: Kathleen Schoofs; Annouck Philippron; Piet Pattyn; Katleen De Preter; Francisco Avila Cobos; Jan Koster; Steve Lefever; Jasper Anckaert; Danny De Looze; Jo Vandesompele Journal: Sci Data Date: 2022-03-14 Impact factor: 8.501
Authors: Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva Journal: Cancer Med Date: 2021-12-06 Impact factor: 4.452